5月2日,康宁杰瑞制药-B股价上涨超过20%。此次上涨得益于其KN026关键性II/III期临床试验期中分析达到PFS主要终点,显示出良好的治疗潜力。这一进展有望推动公司新药研发进程。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.